Argonaut Therapeutics

Argonaut Therapeutics is a United Kingdom-based biopharmaceutical company focused on developing next-generation epigenetic therapies for the treatment of cancer. The company specializes in the inhibition of Protein Arginine Methyltransferase 5 (PRMT5), a key enzyme involved in gene expression and cellular proliferation that is frequently dysregulated in various malignancies. Argonaut's lead programs include brain-penetrant PRMT5 inhibitors specifically designed to treat glioblastoma and other solid tumors with high unmet medical needs. By leveraging its deep expertise in the PRMT5 pathway and the arginine methylome, the company aims to deliver precision medicines that overcome the limitations of first-generation epigenetic drugs.